



HIV-infected adults with a CD4 cell count greater than 500 cells/mm³ on long-term combination antiretroviral therapy reach same mortality rates as the general population.

Charlotte Lewden, Geneviève Chêne, Philippe Morlat, Francois Raffi, Michel Dupon, Pierre Dellamonica, Jean-Luc Pellegrin, Christine Katlama, Francois Dabis, Catherine Leport

► To cite this version:

Charlotte Lewden, Geneviève Chêne, Philippe Morlat, Francois Raffi, Michel Dupon, et al.. HIV-infected adults with a CD4 cell count greater than 500 cells/mm³ on long-term combination antiretroviral therapy reach same mortality rates as the general population.. Journal of Acquired Immune Deficiency Syndromes - JAIDS, 2007, 46 (1), pp.72-7. 10.1097/QAI.0b013e318134257a . inserm-00170726

HAL Id: inserm-00170726

<https://inserm.hal.science/inserm-00170726>

Submitted on 1 Sep 2008

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Table 1. Mortality rates and standardized mortality ratio (SMR) in HIV-infected adults, ANRS CO8 APROCO-COPILOTE and ANRS CO3 AQUITAINE cohorts, 1997-2005, overall and according to gender, HIV transmission group and co-infection by hepatitis C virus at baseline.

	N	Median follow-up (years)	(interquartile range, IQR)	Person-years (PY)	Deaths (n)	Rates (/100 PY)	(95% CI)	SMR	(95% CI)
Overall	2435	6.8	(4.1-7.9)	13954	288	2.1	(1.8-2.3)	7.0	(6.2-7.8)
Men	1864	6.9	(4.1-7.9)	10777	226	2.1	(1.8-2.4)	4.8	(4.2-5.5)
Women	571	6.5	(3.9-7.8)	3177	62	2.0	(1.5-2.4)	13.0	(10.0-16.7)
Hepatitis C									
positive	574	6.4	(3.6-7.8)	3163	99	3.1	(2.5-3.7)	13.9	(11.3-17.0)
negative	1434	7.0	(4.4-7.9)	8519	120	1.4	(1.2-1.7)	4.4	(3.6-5.2)
HIV transmission group									
injecting drug users	527	6.2	(3.2-7.8)	2849	93	3.3	(2.6-3.9)	16.3	(13.2-20.0)
others	1908	6.9	(4.2-7.9)	11104	195	1.8	(1.5-2.0)	5.5	(4.7-6.3)

HIV: Human Immunodeficiency Virus; CI: confidence interval

Table 2. Mortality rates and standardized mortality ratio (SMR) in HIV-infected adults, ANRS CO8 APROCO-COPILOTE and ANRS CO3 AQUITAINE cohorts, 1997-2005, according to cumulated time spent within each category of CD4 cell count.

	N	Median	(interquartile	Person-years	Deaths	Rates	(95% CI)	SMR	(95% CI)
	patients	time spent	range, IQR)	(PY)	(n)	(/100			
		(years)				PY)			
CD4 cell count $\geq 500/\text{mm}^3$	1208	4.5	(2.1-7.0)	5402	37	0.7	(0.5-0.9)	2.5	(1.8-3.5)
CD4 cell count 350 to 499/ mm^3	1263	2.0	(1.0-4.0)	3446	40	1.2	(0.8-1.5)	3.5	(2.5-4.8)
CD4 cell count 200 to 349/ mm^3	1296	2.0	(0.6-3.9)	3178	56	1.8	(1.3-2.2)	5.6	(4.2-7.2)
CD4 cell count $<200/\text{mm}^3$	1118	0.6	(0.2-2.7)	1928	155	8.0	(6.8-9.3)	30.3	(25.8-35.5)

HIV: Human Immunodeficiency Virus; CI: confidence interval

Table 3. Mortality rates and standardized mortality ratio (SMR) in HIV-infected adults, ANRS CO8 APROCO-COPILOTE and ANRS CO3 AQUITAINE cohorts, 1997-2005, according to cumulated time spent with CD4 cell count ≥ 500 /mm³, after the time of truncation[§].

Time of truncation [§]	Total			Patients with CD4 ≥ 500 /mm ³ after the time of truncation								
	N	Person-	Deaths	N	Median	(interquartile	PY	Deaths	Rates	(95% CI)	SMR	(95% CI)
after initiation of cART (year)	patients	years (PY)	(n)	patients	time spent (years)	range, IQR)		(n)	(/100 PY)			
0	2435	13954	288	1208	4.5	(2.1-7.0)	5402	37	0.7	(0.5-0.9)	2.5	(1.8-3.5)
1	2182	11685	208	1156	4.2	(2.1-6.4)	4817	29	0.6	(0.4-0.8)	2.1	(1.4-3.1)
2	2065	9561	176	1083	4.0	(2.1-5.6)	4080	26	0.6	(0.4-0.9)	2.2	(1.4-3.2)
3	1949	7551	141	1031	3.5	(1.8-4.8)	3345	22	0.7	(0.4-0.9)	2.1	(1.3-3.2)
4	1835	5660	108	967	3.0	(1.5-3.8)	2606	18	0.7	(0.4-1.0)	2.1	(1.3-3.4)
5	1648	3915	62	864	2.4	(1.4-3.0)	1880	12	0.6	(0.3-1.0)	1.9	(1.0-3.2)
6	1430	2389	25	763	1.6	(1.0-2.2)	1189	2	0.2	(0.0-0.4)	0.5	(0.1-1.6)
7	1143	1084	6	610	0.9	(0.5-1.3)	543	1	0.2	(0.0-0.5)	0.5	(0.0-2.6)

[§]truncation: the time period taken into account starts 1, 2, 3,... years after initiation of cART

HIV: Human Immunodeficiency Virus; cART: combination antiretroviral therapy; CI: confidence interval

Table 4. Mortality rates and standardized mortality ratio (SMR) in HIV-infected adults, ANRS CO8 APROCO-COPILOTE and ANRS CO3 AQUITAINE cohorts, 1997-2005, according to time spent with CD4 cell count between 350 and 499 /mm³, after the time of truncation^s.

Time of truncation ^s after initiation of cART (year)	Total			Patients with CD4 350 to 499 /mm ³ after the time of truncation								
	N patients	Person- years (PY)	Deaths (n)	N patients	Median time spent (years)	(interquartile range, IQR)	PY	Deaths (n)	Rates (/100 PY)	(95% CI)	SMR	(95% CI)
0	2435	13954	288	1263	2.0	(1.0-4.0)	3446	40	1.2	(0.8-1.5)	3.5	(2.5-4.8)
1	2182	11685	208	1036	2.5	(1.4-4.0)	2960	35	1.2	(0.8-1.6)	3.4	(2.4-4.8)
2	2065	9561	176	915	2.2	(1.4-3.7)	2434	29	1.2	(0.8-1.6)	3.3	(2.2-4.7)
3	1949	7551	141	816	2.0	(1.1-3.4)	1925	26	1.4	(0.8-1.9)	3.6	(2.3-5.2)
4	1835	5660	108	705	1.9	(1.0-3.0)	1430	20	1.4	(0.8-2.0)	3.5	(2.2-5.5)
5	1648	3915	62	557	1.7	(0.8-2.7)	971	10	1.0	(0.4-1.7)	2.5	(1.2-4.6)
6	1430	2389	25	410	1.5	(0.7-2.0)	572	5	0.9	(0.1-1.6)	2.0	(0.7-4.8)
7	1143	1084	6	286	0.8	(0.5-1.3)	257	2	0.8	(0.0-1.9)	1.9	(0.2-6.7)

^struncation: the time period taken into account starts 1, 2, 3,... years after initiation of cART

HIV: Human Immunodeficiency Virus; cART: combination antiretroviral therapy; CI: confidence interval